FINWIRES · TerminalLIVE
FINWIRES

Swiss Market Index Recovers; Sika, PolyPeptide Group Shares Jump

-- The blue-chip Swiss Market Index bounced back on Tuesday, closing 0.94% higher, as investors digest the latest economy-related and corporate releases while keeping an eye on geopolitical developments.

On the macroeconomic front, the International Monetary Fund lowered its 2026 global growth forecast to 3.1% in its April World Economic Outlook report, down by 0.2 percentage point from its previous estimate, under the assumption that the ongoing conflict in the Middle East remains limited in duration and scope. For 2027, the global growth is still expected to stand at 3.2%.

For the euro area, the economic growth projections for 2026 and 2027 were both trimmed by 0.2 pp to 1.1% and 1.2%, respectively, while the estimates for the UK were cut by 0.5 pp and 0.2 pp to 0.8% and 1.3%.

Back home, Swiss President Guy Parmelin and Federal Councilor Karin Keller-Sutter are set to attend the 2026 IMF and World Bank Spring Meetings and G20 finance ministers meeting in the US this week, according to Switzerland's Federal Council. Swiss National Bank (SNBN.SW) Governing Board Chairman Martin Schlegel will also be part of the delegation.

"The Spring Meetings will focus on global economic and development policy challenges. In the current environment of geopolitical conflicts and trade tensions, it is particularly important for Switzerland to advocate reliable economic relations and open markets in multilateral bodies and bilateral contacts. Healthy public finances, price stability and a robust global monetary and financial system are also crucial for a resilient economy and lasting prosperity," the government said.

Over to corporates, Sika (SIKA.SW) reported a 7% year-over-year drop in first-quarter net sales to 2.49 billion francs. The result was dented by a foreign currency impact of 213 million francs, which the Swiss specialty chemicals group mainly attributed to the franc's strength against Asian currencies and the US dollar. For full-year 2026, the company reaffirmed its sales growth guidance of between 1% and 4% in local currencies. The stock gained 7.94% at closing.

PolyPeptide Group (PPGN.SW) also saw its shares rise 4.46% after disclosing that it is at an early stage of reviewing potential strategic options to further improve its long-term value for shareholders. Amid market chatter that it drew takeover interest from certain investors, the Swiss contract development and manufacturing organization noted that it has yet to decide on the review.

相关文章

Asia

Dizal Pharma将在美国临床肿瘤学会年会上公布三种药物的研究成果。

据周三在上海证券交易所发布的公告显示,江苏迪扎尔制药(SHA:688192)表示,将在美国临床肿瘤学会(ASCO)年会上公布其新药sunvozertinib片剂、golidocitinib胶囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008均用于治疗非小细胞肺癌,而golidocitinib则用于治疗T细胞淋巴瘤。研究结果显示,这些药物均取得了积极成果,尤其是DZD6008,其具有显著的抗肿瘤活性且安全性良好。 该生物技术公司的股价在午盘交易中上涨不到2%。

$SHA:688192
Asia

Critica将于3月季度启动西澳大利亚稀土项目范围界定研究。

据周三提交给澳大利亚证券交易所的文件显示,Critica(ASX:CRI)表示,位于西澳大利亚的Jupiter稀土项目的初步研究已于今年3月季度正式启动。 该研究整合了选矿、下游加工、基础设施和开发假设,旨在确定一个基准开发路径。 公司计划在6月季度继续完成Jupiter项目140个钻孔的资源升级钻探工作。此外,公司还计划准备并运送20,000公斤散装样品进行中试规模处理,以支持持续的优化、性能提升和中间精矿的生产。

$ASX:CRI
Asia

北太平洋银行的收购要约确保了对卡里尔银行的控制权

北太平洋银行(东京证券交易所代码:8524)周三在东京证券交易所发布公告称,其对Career Bank的股份收购要约已获成功,持股比例增至88.26%,使Career Bank成为其子公司。 北太平洋银行此次收购了852,487股Career Bank股份,超过了完成交易所需的最低收购数量。 结算将于4月28日开始,届时Career Bank将正式并入北太平洋银行的财务报表。 北太平洋银行计划启动相关程序,使Career Bank成为其全资子公司,并将其股票从札幌证券交易所退市。此次收购总成本约为15亿日元。

$TYO:8524